Search
Lexeo Therapeutics Inc
LXEOAdd to Watchlist
4.690USD
+0.240+5.39%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
347.45MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.39%
5 Days
-1.26%
1 Month
-1.88%
6 Months
-51.20%
Year to Date
-52.77%
1 Year
+5.39%
Key Figures
4.540Open
4.734High
825.58KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.11%Turnover Ratio
4.450Prev. Close
4.525Low
2.72MTurnover
LossP/E Static
1.50P/B
0.00%Div Yield TTM
-46.54%ROA
10.99052wk High
1.20Volume Ratio
-98.33MNet Profit
74.08MShares
-1.1260EPS TTM
--Beta
-54.75%ROE
2.66052wk Low
4.69%Amplitude
100.00%Gross Margin
347.45MMarket Cap
-1.71Reward/Risk
4.05%Risk Rate
TradingKey Stock Score of Lexeo Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Lexeo Therapeutics Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 21.89.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Lexeo Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Lexeo Therapeutics Inc Highlights
StrengthsRisks
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -4.17, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 88.41M shares, increasing 14.92% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 135.15K shares of this stock.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
21.889
Target Price
+391.89%
Upside Space
Lexeo Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Lexeo Therapeutics Inc Info
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Ticker SymbolLXEO
CompanyLexeo Therapeutics Inc
CEOTownsend (R. Nolan)
Websitehttps://www.lexeotx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Lexeo Therapeutics Inc (LXEO)?
The current price of Lexeo Therapeutics Inc (LXEO) is 4.69.
What is the symbol of Lexeo Therapeutics Inc?
The ticker symbol of Lexeo Therapeutics Inc is LXEO.
What is the 52-week high of Lexeo Therapeutics Inc?
The 52-week high of Lexeo Therapeutics Inc is 10.99.
What is the 52-week low of Lexeo Therapeutics Inc?
The 52-week low of Lexeo Therapeutics Inc is 2.66.
What is the market capitalization of Lexeo Therapeutics Inc?
The market capitalization of Lexeo Therapeutics Inc is 347.45M.
Is Lexeo Therapeutics Inc (LXEO) currently rated as Buy, Hold, or Sell?
According to analysts, Lexeo Therapeutics Inc (LXEO) has an overall rating of STRONG BUY, with a price target of 21.89.
What is the Earnings Per Share (EPS TTM) of Lexeo Therapeutics Inc (LXEO)?
The Earnings Per Share (EPS TTM) of Lexeo Therapeutics Inc (LXEO) is -1.86.